Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Revenue projections:

The projected decline in Bristol-Myers Squibb Company's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio	1.532000
forwardPE	9.361995
debtToEquity	201.859000
earningsGrowth	1.531000
revenueGrowth	0.057000
grossMargins	0.716610
operatingMargins	0.344180
trailingEps	4.470000
forwardEps	6.564840

A current ratio of 1.532 for Bristol-Myers Squibb Company implies that the company has ample liquidity to meet its short-term debts. Bristol-Myers Squibb Company's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
BMY's high debt-to-equity ratio signals that the company is heavily leveraged. This suggests BMY may be relying more on debt than equity to finance its operations, which could expose the company to greater financial risk in challenging economic conditions.
With positive gross and operating margins, Bristol-Myers Squibb Company demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
BMY's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with BMY anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for BMY have consistently been revised upward, suggesting that analysts are increasingly optimistic about the company's performance. This trend reflects a positive outlook for BMY's future.

Insider Transactions:

5 sell transactions of BMY were recorded, with market price hovering near 57.14000015258789.No sell transactions were carried out during the period under review.More buys than sells have been occurring around the current price levels of BMY, potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

Analysts have been favoring BMY with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning BMY as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.